High serum nitrates levels in non-survivor COVID-19 patients.

L Lorente, F Gómez-Bernal, M M Martín, J A Navarro-Gonzálvez, M Argueso, A Perez, L Ramos-Gómez, J Solé-Violán, J A Marcos Y Ramos, N Ojeda, A Jiménez

Journal: Medicina intensiva 2022;46(3):132-139

PMID: 35221002

Abstract

OBJECTIVE

Higher blood nitrate and nitrite levels have been found in coronavirus disease 2019 (COVID-19) patients than in healthy subjects. The present study explores the potential association between serum nitrate levels and mortality in COVID-19 patients.

DESIGN

A prospective observation study was carried out.

SETTING

Eight Intensive Care Units (ICUs) from 6 hospitals in the Canary Islands (Spain).

PATIENTS

COVID-19 patients admitted to the ICU.

INTERVENTIONS

Determination of serum nitrate levels at ICU admission.

MAIN VARIABLE OF INTEREST

Mortality at 30 days.

RESULTS

Non-surviving (n=11) compared to surviving patients (n=42) showed higher APACHE-II (p<0.001) and SOFA scores (p=0.004), and higher serum nitrate levels (p=0.001). Logistic regression analyses showed serum nitrate levels to be associated to 30-day mortality after controlling for SOFA (OR=1.021; 95%CI=1.006-1.036; p=0.01) or APACHE-II (OR=1.023; 95%CI=1.006-1.041; p=0.01). There were no differences in the area under the curve (AUC) for mortality prediction by serum nitrate levels (AUC=83%; 95%CI=73-92%; p<0.001), APACHE II (AUC=85%; 95%CI=75-96%; p<0.001) and SOFA (AUC=78%; 95%CI=63-92%; p=0.005) based on the DeLong method. The Kaplan-Meier analysis found patients with serum nitrates levels>68.4μmol/l to have a higher mortality rate (hazard ratio=138.8; 95%CI=22.3-863.9; p<0.001).

CONCLUSIONS

The main novel finding was the association between serum nitrate levels and mortality in COVID-19 patients controlling for the SOFA or APACHE-II scores, though larger studies are needed to confirm this observation.

Copyright © 2020 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Address: Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain. Electronic address: [email protected].; Laboratory Department, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.; Intensive Care Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.; Intensive Care Unit, Complejo Hospitalario Universitario Insular, Las Palmas de Gran Canaria, Spain.; Internal Intensive Care Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.; Intensive Care Unit, Hospital General La Palma, Breña Alta, Santa Cruz de Tenerife, Spain.; Intensive Care Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.; Intensive Care Unit, Hospital Doctor José Molina Orosa, Arrecife, Las Palmas, Spain.; Department of Anesthesiology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.; Research Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.